Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
about
Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipaseThe sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting proteinSNX1 defines an early endosomal recycling exit for sortilin and mannose 6-phosphate receptorsSortilin associates with Trk receptors to enhance anterograde transport and neurotrophin signaling.Characterization of sorCS1, an alternatively spliced receptor with completely different cytoplasmic domains that mediate different trafficking in cellsSortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway.Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor familiesWNK4 enhances the degradation of NCC through a sortilin-mediated lysosomal pathwaySpadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design.Identification of the first small-molecule ligand of the neuronal receptor sortilin and structure determination of the receptor-ligand complexRevisiting the structure of the Vps10 domain of human sortilin and its interaction with neurotensinThe sorLA cytoplasmic domain interacts with GGA1 and -2 and defines minimum requirements for GGA bindingSortilin, encoded by the cardiovascular risk gene SORT1, and its suggested functions in cardiovascular diseaseA new role under sortilin's belt in cancerReceptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry diseaseMannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cellsDisruption of the expression of the proprotein convertase PC7 reduces BDNF production and affects learning and memory in mice.Functional organization of the sortilin Vps10p domain.Identification of a linear epitope in sortilin that partakes in pro-neurotrophin binding.SorCS3 does not require propeptide cleavage to bind nerve growth factor.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.ProNGF mediates death of Natural Killer cells through activation of the p75NTR-sortilin complex.Sortilin participates in light-dependent photoreceptor degeneration in vivo.Targeting two-pore domain K(+) channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept.Retroinverso analogs of spadin display increased antidepressant effectsSortilin associates with transforming growth factor-beta family proteins to enhance lysosome-mediated degradation.Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis.Progranulin: a promising therapeutic target for rheumatoid arthritis.In vitro and in vivo regulation of synaptogenesis by the novel antidepressant spadin.Multi-tasking by the p75 neurotrophin receptor: sortilin things out?Neurotensin and its receptors in the control of glucose homeostasis.Mapping of the interaction site between sortilin and the p75 neurotrophin receptor reveals a regulatory role for the sortilin intracellular domain in p75 neurotrophin receptor shedding and apoptosisOral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells.The role of neurotensin in central nervous system pathophysiology: what is the evidence?ProBDNF and mature BDNF as punishment and reward signals for synapse elimination at mouse neuromuscular junctionsTLR signals posttranscriptionally regulate the cytokine trafficking mediator sortilin.Increased serum levels of sortilin are associated with depression and correlated with BDNF and VEGF.Sortilin and SorLA regulate neuronal sorting of trophic and dementia-linked proteins.Sorting receptor sortilin-a culprit in cardiovascular and neurological diseases.The sugar code in neuronal physiology.
P2860
Q22009071-3529BE32-83EE-46CA-96DE-EECE212DFD40Q24291185-9EAB42F9-73E5-4E64-9212-7D7F8E627A9DQ24304125-26080DA0-DECC-4D1C-86F1-673A5DF7A527Q24307989-A8F52C5F-26DB-45D4-92D9-617981C39878Q24336636-7BDEA0FE-885C-4193-AAD8-77A67CCD4483Q24532072-048B638E-E70F-4FAD-A125-320FBCB08855Q24651670-29468F40-F19B-479C-A3FA-FA367B532DB0Q24652877-CF5FEAC6-C92A-46BA-B062-5A2420357901Q27324635-85586B97-8360-4D74-9CF8-8DEE37CC0CB5Q27681761-862155F4-1EBB-4493-B8E0-3C6C03BF1DABQ27684514-B1A40F66-B5F7-4139-98CB-CF6ADC2FAE64Q28217015-8B533FE8-D335-4D38-A8D3-3350641313CFQ28257511-657AF748-8A09-4F0A-931C-21662AE64079Q28274718-73B4D599-F99A-4B8B-B8AA-A11806A17794Q28477142-77EB3CFA-726F-4A7B-803F-13D4A2710D06Q28727768-3B4A1623-BF80-49CB-9128-17528619DBDFQ30439831-47ABD321-8F96-4653-B180-06CBF564C16CQ30958722-54E84393-B42D-43F9-BEE6-C6EBEAB4FB82Q30977865-30F1087D-1FC3-4E39-9AFE-86455526253CQ33292479-28B6E945-CEE6-4EB5-BA2C-F63A0048B76BQ33599961-30F4965C-1395-4EF0-948C-3A2295380A56Q34117630-A1CD4BFB-AD53-44F6-AFEE-4053B0CE307CQ34257346-6B1C2064-DE29-4DEB-9506-9E75D12D43C2Q34994509-B54B611A-2A9E-4FA2-A992-08F9F29F476DQ34996777-706635E1-7501-496D-9217-FABFEE23084FQ35065290-D9075798-FD1B-46BA-9C39-9A2E76B48C97Q35145355-CCC4D12E-BC75-43AE-A1A3-5BE719846B59Q35182029-01DDD16F-AF38-4987-8E13-E13736E83C8CQ35538532-6DD89779-61A3-42C4-93F3-26CF567949DEQ35911455-4EE82025-2DB4-46B8-974E-1EA56499F52EQ36449538-0EC7070F-0024-4144-8D12-BBCBE9464BEBQ36481872-AFF1F50E-EE42-4C2A-873B-B7C171A0F7BAQ36504504-D7D1500A-4DD5-4758-9D0F-8F43E379B828Q36544566-122F4090-D5FB-42C9-834D-510CB440F472Q36928489-BCB7DA5E-0FF4-494D-9BAA-B8B4717164EFQ36934133-AB03CBCA-3EA2-4233-9C41-BD3FFAFB7C7DQ37347646-DC719ACC-EA2F-4162-9295-CF127DB5F96CQ37980650-7024BBD4-3810-4960-AB02-DA066411369DQ38212601-06E23376-FBF8-4609-91D8-F6EC0C67101BQ38289683-EF4E15B8-6F7E-4284-A824-E6C625E10BAC
P2860
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding
@nl
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
@ast
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
@en
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
@en-gb
type
label
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding
@nl
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
@ast
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
@en
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
@en-gb
prefLabel
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding
@nl
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
@ast
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
@en
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
@en-gb
P2093
P2860
P3181
P356
P1433
P1476
Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding.
@en
P2093
Gliemann J
Jacobsen C
Jacobsen L
Munck Petersen C
Nielsen MS
P2860
P304
P3181
P356
10.1093/EMBOJ/18.3.595
P407
P577
1999-02-01T00:00:00Z